Evidence map›Paper›PMID 39431656›Full record

ArticleJournal of research in health sciences2024

Association of

Ali Khalouei, Yaser Masoumi-Ardakani, Abdollah Jafarzaheh, Behjat Kalantari Khandani, Farnaz Sedghy, Arezu Khosravi Mashizi, Mohammad Mehdi Yaghoobi, Mohammadreza Zangouey, Beydolah Shahouzehi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of research in health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ali KhaloueiPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0002-7638-1271
Yaser Masoumi-ArdakaniStudent Research Committee, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0002-6488-4103
Abdollah JafarzahehDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Behjat Kalantari KhandaniDepartment of Hematology and Oncology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Farnaz SedghyDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
Arezu Khosravi MashiziDepartment of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Mohammad Mehdi YaghoobiResearch Department of Biotechnology, Institute of Science and High Technology and Environmental Sciences, Graduate University of Advanced Technology, Kerman, Iran.
Mohammadreza ZangoueyDepartment of Immunology, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Beydolah ShahouzehiCardiovascular Research Center, Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolymorphisms within the excision repair cross-complementation group 1 (

methodsGenomic DNA was extracted from the peripheral blood samples of 83 NSCLC patients and 119 healthy individuals. The genetic diversity of SNPs rs3212986 and rs11615 was determined using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The RFLP results were confirmed through sequencing.

resultsThe TT genotype of the rs11615 SNP was associated with a higher risk of NSCLC development (odds ratio: 3.900, 95% confidence interval: 0.603, 22.866, P=0.050). Furthermore, the AA genotype of rs3212986 was related to a higher risk of NSCLC development (OR: 2.531, 95% CI: 1.017, 6.300,

conclusionThe rs11615-related TT genotype and the rs3212986-related AA genotype may be associated with a higher risk of lung cancer development.

Indexed as

Carcinoma, Non-Small-Cell LungDNA-Binding ProteinsEndonucleasesGenetic Predisposition to DiseaseGenotypeLung NeoplasmsPolymorphism, Single NucleotideAdultAgedCase-Control StudiesFemaleHumansIranMaleMiddle AgedPolymorphism, Restriction Fragment LengthDNA-Binding ProteinsEndonucleasesERCC1 protein, humanChemotherapyERCC1 geneLung cancerPCR-RFLPPharmacogenetic studiesPolymorphism

Identifiers

PMID39431656
PMCPMC11492521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.